Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial.
We investigated the utility of ultrasonography for assessing facial lipoatrophy changes in HIV-infected adults receiving antiretroviral therapy who participated in a 48-week, randomized, placebo-controlled trial of rosiglitazone. Ultrasound was performed at weeks 0, 24 and 48 to determine the subcutaneous fat thickness over the malar bone. Changes in facial fat assessed by ultrasonography did not correlate significantly with more established objective measures of lipoatrophy severity. The measurement of malar fat using ultrasonography is not recommended.
Carey
Dianne
D
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia.
Wand
Handan
H
Martin
Allison
A
Rothwell
Sharyn
S
Emery
Sean
S
Cooper
David A
DA
Carr
Andrew
A
D019380:Anti-HIV Agents / Q000627:therapeutic use; D005145:Face; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000473:pathology; D039682:HIV-Associated Lipodystrophy Syndrome / Q000000981:diagnostic imaging* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use; D014463:Ultrasonography
D019380:Anti-HIV Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone